AR034044A1 - Composicion para el tratamiento reconstituyente en enfermedades de cartilago - Google Patents

Composicion para el tratamiento reconstituyente en enfermedades de cartilago

Info

Publication number
AR034044A1
AR034044A1 ARP020101911A ARP020101911A AR034044A1 AR 034044 A1 AR034044 A1 AR 034044A1 AR P020101911 A ARP020101911 A AR P020101911A AR P020101911 A ARP020101911 A AR P020101911A AR 034044 A1 AR034044 A1 AR 034044A1
Authority
AR
Argentina
Prior art keywords
composition
cartilage
pde4 inhibitor
biocompatible
treatment
Prior art date
Application number
ARP020101911A
Other languages
English (en)
Inventor
M Takigawa
N Sakurai
T Takagi
N Yanaka
Y Horikiri
Takashi Tamura
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of AR034044A1 publication Critical patent/AR034044A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Una composición para el tratamiento regenerativo de la enfermedad del cartílago que comprende un inhibidor de PDE4 como ingrediente activo, específicamente se provee una composición que comprende un inhibidor de PDE4 y un polímero biocompatible y biodegradable, dicha composición, cuando es formulada en una forma adecuada para que sea administrada localmente en la región del cartílago afectado, como preparación de microesfera, puede proveer una composición farmacéutica que demuestra un efecto excelente en el tratamiento regenerativo del cartílago. El polímero biocompatible y biodegradable puede ser uno o más polímeros seleccionados del grupo que consiste de ácido poliláctico, copolímero de ácido láctico-ácido glicólico y copolímero de ácido 2-hidroxibutírico-ácido glicólico, con un peso molecular promedio de 2.000-800.000. El inhibidor de PDE4 es un compuesto que posee una estructura parcial, que tiene actividad inhibitoria de PDE4, como la siguiente (A) naftaleno o una estructura química análoga al mismo; o (B) 3-ciclopentiloxi-4-metoxifenilo o una estructura química análoga al mismo. La composición es útil en la soldadura de fractura de personas mayores y pacientes diabéticos o con osteosporosis.
ARP020101911A 2001-05-23 2002-05-23 Composicion para el tratamiento reconstituyente en enfermedades de cartilago AR034044A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001154048 2001-05-23

Publications (1)

Publication Number Publication Date
AR034044A1 true AR034044A1 (es) 2004-01-21

Family

ID=18998464

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101911A AR034044A1 (es) 2001-05-23 2002-05-23 Composicion para el tratamiento reconstituyente en enfermedades de cartilago

Country Status (10)

Country Link
US (3) US20040180900A1 (es)
EP (1) EP1389467B1 (es)
JP (2) JP4510383B2 (es)
KR (1) KR20040007583A (es)
CN (1) CN1537018A (es)
AR (1) AR034044A1 (es)
CA (1) CA2447618A1 (es)
ES (1) ES2427930T3 (es)
MX (1) MXPA03010672A (es)
WO (1) WO2002094320A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618652B2 (en) * 2001-03-23 2009-11-17 Hepmarin As Glycosaminoglycan anticoagulants derived from fish
CN1537018A (zh) * 2001-05-23 2004-10-13 田边制药株式会社 一种用于软骨疾病再生治疗的组合物
TWI221838B (en) 2001-08-09 2004-10-11 Tanabe Seiyaku Co Pyrazinoisoquinoline compound or naphthalene compound
FR2876582B1 (fr) * 2004-10-15 2007-01-05 Centre Nat Rech Scient Cnrse Utilisation de derives de pyrrolo-pyrazines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
TWI339578B (en) * 2004-10-29 2011-04-01 Mitsubishi Tanabe Pharma Corp Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions
AU2006311577B2 (en) 2005-11-09 2013-02-07 Zalicus Inc. Methods, compositions, and kits for the treatment of medical conditions
US20080038557A1 (en) * 2006-08-08 2008-02-14 The Procter & Gamble Company Process for making collapsible water-containing capsules
US20100291027A1 (en) * 2009-05-14 2010-11-18 Jason Campbell Hyaluronic acid (ha) injection vehicle
ITPI20090106A1 (it) * 2009-08-27 2011-02-28 Eros Dinelli Dispositivo medico per la prevenzione ed il trattamento di condropatie
WO2011031642A2 (en) * 2009-09-08 2011-03-17 Musculoskeletal Transplant Foundation Inc. Tissue engineered meniscus repair composition
US20110059178A1 (en) * 2009-09-08 2011-03-10 Musculoskeletal Transplant Foundation Inc. Tissue Engineered Meniscus Repair Composition

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
NL7800644A (nl) * 1978-01-19 1979-07-23 Stamicarbon Werkwijze voor de bereiding van 2-pyrrolidon.
JPS5619324A (en) 1979-07-24 1981-02-24 Asahi Electronics Wheel passage type anchoring clamp
US4542025A (en) * 1982-07-29 1985-09-17 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
JPS6067417A (ja) 1983-09-24 1985-04-17 Tetsuo Kato 生体内代謝性マイクロカプセルの製法
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
GB8406906D0 (en) 1984-03-16 1984-04-18 Akzo Nv Benzo-thiazole and benzothiophene derivatives
DK159431C (da) 1984-05-10 1991-03-18 Byk Gulden Lomberg Chem Fab 6-phenyl-3(2h)-pyridazinoner, fremgangsmaade til fremstilling deraf, laegemidler indeholdende disse samt anvendelse af forbindelserne til fremstilling af laegemidler
JPH0720859B2 (ja) 1985-02-07 1995-03-08 武田薬品工業株式会社 マイクロカプセルの製造法
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US5939388A (en) 1986-07-01 1999-08-17 Rosen; Vicki A. Methods of administering BMP-5 compositions
EP0260817B1 (en) 1986-08-21 1991-05-15 Pfizer Inc. Quinazolinediones and pyridopyrimidinediones
JPH0725689B2 (ja) 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
US5000886A (en) * 1987-05-26 1991-03-19 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules and process of making the same
DE3738228A1 (de) 1987-11-11 1989-05-24 Hoechst Ag Verfahren zur herstellung von bioabbaubaren mikrokapseln wasserloeslicher peptide und proteine sowie nach diesem verfahren erhaltene mikrokapseln
JPH01305929A (ja) 1988-06-02 1989-12-11 Toshiba Corp Ｘ線診断装置
WO1990009783A1 (en) 1989-02-22 1990-09-07 Massachusetts Institute Of Technology Delivery system for controlled release of bioactive factors
GB8913889D0 (en) 1989-06-16 1989-08-02 May & Baker Ltd New compositions of matter
WO1991001720A1 (en) 1989-08-07 1991-02-21 Herman Wade Schlameus Composition and method of promoting hard tissue healing
JP2578001B2 (ja) 1989-12-11 1997-02-05 明治製菓株式会社 抗痴呆薬
GB8929208D0 (en) * 1989-12-27 1990-02-28 Almirall Lab New xanthine derivatives
JPH07107055B1 (es) 1990-04-25 1995-11-15
US5288496A (en) * 1990-05-15 1994-02-22 Stolle Research & Development Corporation Growth promoters for animals
ATE203020T1 (de) 1990-05-30 2001-07-15 Takeda Chemical Industries Ltd Schwefel enthaltende heterocyclische verbindungen
EP0459505B1 (en) 1990-06-01 1996-10-02 Kyowa Hakko Kogyo Co., Ltd. Imidazonaphthyridine derivatives
IE71647B1 (en) 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
US5171217A (en) * 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
YU48420B (sh) 1991-03-25 1998-07-10 Hoechst Aktiengesellschaft Postupak za dobijanje biološki razgradljivih mikročestica sa dugotrajnim delovanjem
JPH0558882A (ja) 1991-09-04 1993-03-09 Yoshiaki Kawashima ナノカプセルの製造法
JP3205884B2 (ja) 1991-10-01 2001-09-04 武田薬品工業株式会社 凝集防止剤をコーティングした徐放性微粒子製剤
PH31245A (en) 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
JP3042156B2 (ja) 1992-02-20 2000-05-15 田辺製薬株式会社 ナフタレン誘導体、その製法及びその合成中間体
US5552438A (en) * 1992-04-02 1996-09-03 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
DE4223169C1 (de) * 1992-07-10 1993-11-25 Ferring Arzneimittel Gmbh Verfahren zur Mikroverkapselung wasserlöslicher Wirkstoffe
WO1994002455A1 (en) 1992-07-15 1994-02-03 Smithkline Beecham Corporation Benzenepropanoic acid disodium salt dihydrate
JP2651320B2 (ja) 1992-07-16 1997-09-10 田辺製薬株式会社 徐放性マイクロスフェア製剤の製造方法
PT652868E (pt) * 1992-07-28 2005-01-31 Aventis Pharma Ltd Inibidores da fosfodiesterase do amp ciclico
JP2911732B2 (ja) 1992-10-01 1999-06-23 田辺製薬株式会社 徐放性多核マイクロスフェア製剤およびその製法
US5455252A (en) 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines
JPH06305983A (ja) 1993-04-21 1994-11-01 Sangi Co Ltd 薬剤徐放用製剤
US5459151A (en) 1993-04-30 1995-10-17 American Home Products Corporation N-acyl substituted phenyl piperidines as bronchodilators and antiinflammatory agents
GB9309324D0 (en) 1993-05-06 1993-06-16 Bayer Ag Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives
GB9312853D0 (en) * 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US5605914A (en) * 1993-07-02 1997-02-25 Celgene Corporation Imides
ATE218549T1 (de) * 1993-07-28 2002-06-15 Aventis Pharma Ltd Verbindungen als pde iv und tnf inhibitoren
JPH07101861A (ja) * 1993-08-10 1995-04-18 Tanabe Seiyaku Co Ltd 抗喘息薬
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
US5716967A (en) * 1993-11-26 1998-02-10 Pfizer Inc. Isoxazoline compounds as antiinflammatory agents
US5502072A (en) * 1993-11-26 1996-03-26 Pfizer Inc. Substituted oxindoles
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
GB9412383D0 (en) 1994-06-21 1994-08-10 Celltech Ltd Chemical compound
GB9412672D0 (en) 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
CA2193725A1 (en) 1994-06-24 1996-01-04 David Cavalla Aryl derivative compounds and uses to inhibit phosphodiesterase iv acti vity
MX9701600A (es) 1994-08-29 1997-05-31 Yamanouchi Pharma Co Ltd Derivados de naftiridina novedosos y composicion medicinal de los mismos.
JP3790567B2 (ja) 1994-09-30 2006-06-28 武田薬品工業株式会社 徐放剤
US5614515A (en) * 1994-11-17 1997-03-25 University Of Southern California Lazaroid-based compositions and method for preventing adhesion formation using the same
ATE252894T1 (de) 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
EP0814778B1 (de) * 1995-03-10 2001-06-13 Roche Diagnostics GmbH Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung
TW332201B (en) * 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives
DE19514568A1 (de) * 1995-04-20 1996-10-24 Merck Patent Gmbh Arylalkyl-pyridazinone
US5922253A (en) * 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
US5910492A (en) * 1995-06-05 1999-06-08 Takeda Chemical Industries, Ltd. Osteogenic promoting pharmaceutical composition
JP2992677B2 (ja) 1995-06-05 1999-12-20 武田薬品工業株式会社 骨形成促進医薬組成物
IL118469A (en) * 1995-06-15 2000-08-13 Tanabe Seiyaku Co Naphthalene derivatives their preparation and intermediates thereof
JP3033090B2 (ja) * 1995-06-15 2000-04-17 田辺製薬株式会社 ナフタレン誘導体、その製法及びその合成中間体
US5728844A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
JPH09110678A (ja) 1995-10-19 1997-04-28 Tanabe Seiyaku Co Ltd 被覆マイクロスフェア製剤およびその製法
GB9523267D0 (en) 1995-11-14 1996-01-17 Sandoz Ltd Organic compounds
GB9603723D0 (en) 1996-02-22 1996-04-24 Merck & Co Inc Diphenyl pyridyl derivatives as pde iv inhibitors
CA2192773C (en) * 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
EP0873311A1 (en) * 1995-12-15 1998-10-28 Merck Frosst Canada Inc. Tri-aryl ethane derivatives as pde iv inhibitors
CA2239053C (en) 1995-12-15 2005-04-26 Merck Frosst Canada Inc. Diphenyl pyridyl ethane derivatives as pde iv inhibitors
JP3191004B2 (ja) 1995-12-15 2001-07-23 武田薬品工業株式会社 マイクロスフェアの製造法
JP3765338B2 (ja) 1995-12-15 2006-04-12 武田薬品工業株式会社 注射用徐放性製剤の製造法
JPH09169665A (ja) 1995-12-21 1997-06-30 Kenichi Miyamoto 骨粗鬆症治療剤
US6010711A (en) * 1996-01-26 2000-01-04 University Of Rochester Methods, articles and compositions for the pharmacologic inhibition of bone resorption with phosphodiesterase inhibitors
GB9606736D0 (en) 1996-02-19 1996-06-05 Shire International Licensing Therapeutic method
DE19617864A1 (de) * 1996-04-23 1997-10-30 Schering Ag Neue chirale Phenyldihydrofuranone
AU722662B2 (en) * 1996-05-20 2000-08-10 Darwin Discovery Limited Quinoline sulfonamides as TNF inhibitors and as PDE-IV inhibitors
IL126557A (en) * 1996-05-20 2002-09-12 Darwin Discovery Ltd Quinoline (thio) carboxamides inhibiting TNF or PDE-IV and pharmaceutical preparations containing them
GB9614718D0 (en) 1996-07-12 1996-09-04 Bayer Ag 3-ureido-pyridofurans and -pyridothiophenes
TR199900481T2 (xx) 1996-09-04 1999-06-21 Pfizer Inc. �ndazol t�revleri; fosfodiesteraz tip IV inhibit�rleri olarak kullan�mlar�.
BR9712256B1 (pt) 1996-10-02 2011-04-19 composto derivado de 2-ciano imino imidazol, processo de preparação do mesmo e composição.
GB9622386D0 (en) * 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
JP4354016B2 (ja) * 1996-11-29 2009-10-28 株式会社メディサイエンスプラニング 新規プリン誘導体およびこれを含む医薬組成物
JP3951395B2 (ja) 1996-12-13 2007-08-01 田辺製薬株式会社 ピリジン誘導体、その製法及びその合成中間体
ID19155A (id) * 1996-12-13 1998-06-18 Tanabe Seiyaku Co Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya
US6214008B1 (en) * 1997-04-16 2001-04-10 White Spot Ag Biodegradable osteosynthesis implant
FR2762841B1 (fr) 1997-04-30 1999-07-02 Jouveinal Inst Rech Diazepino-indolones inhibitrices de phosphodiesterases iv
FR2764514B1 (fr) * 1997-06-13 1999-09-03 Biopharmex Holding Sa Implant injectable en sous-cutane ou intradermique a bioresorbabilite controlee pour la chirurgie reparatrice ou plastique et la dermatologie esthetique
TW577758B (en) * 1997-10-27 2004-03-01 Ssp Co Ltd Intra-articular preparation for the treatment of arthropathy
YU25400A (sh) * 1997-11-04 2003-07-07 Pfizer Products Inc. Terapeutski aktivna jedinjenja sa indazolom
JP3240593B2 (ja) 1998-02-16 2001-12-17 株式会社高研 可溶性コラーゲンパウダーを担体とする医薬徐放剤
US6451335B1 (en) * 1998-07-02 2002-09-17 Euro-Celtique S.A. Formulations and methods for providing prolonged local anesthesia
JP4979157B2 (ja) * 1998-09-09 2012-07-18 バイオリポックス アーべー 置換されたγ−フェニル−Δ−ラクトンおよびそのアナログならびにこれらに関する使用
AR028986A1 (es) * 1999-02-23 2003-06-04 Smithkline Beecham Corp USO DE UN INHIBIDOR DE PDE4 EN LA FABRICACIoN DE UNA PREPARACIoN DE LIBERACIoN CONTROLADA; FORMULACION DE LIBERACION CONTROLADA PARA EL TRATAMIENTO DE COPD, UN PROCEDIMIENTO PARA SU PREPARACIoN Y COMPOSICIoN FARMACÉUTICA
FR2793684B1 (fr) * 1999-05-17 2001-08-10 Ethypharm Lab Prod Ethiques Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant
EA006685B1 (ru) * 1999-08-21 2006-02-24 Алтана Фарма Аг Синергетическая композиция
JP2001187749A (ja) 1999-10-18 2001-07-10 Tanabe Seiyaku Co Ltd 長期徐放性圧縮成型製剤およびその製造法
KR20020082473A (ko) 1999-12-22 2002-10-31 파마시아 코포레이션 시클로옥시게나제-2 억제제의 지속-방출 조제물
US6348602B1 (en) * 1999-12-23 2002-02-19 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
JP3718708B2 (ja) 2000-01-19 2005-11-24 独立行政法人物質・材料研究機構 リン酸カルシウム系生体用セラミック焼結体およびその製造方法
CZ20022413A3 (cs) * 2000-01-31 2003-08-13 Pfizer Products Inc. Pyrimidinkarboxamidy užitečné jako inhibitory isozymů PDE4
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
WO2001093909A2 (en) * 2000-06-06 2001-12-13 Glaxo Group Limited Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor
NZ524050A (en) 2000-08-11 2005-07-29 Ono Pharmaceutical Co Piperidine derivatives in compounds that have a PDE4 inhibitory activity to treat inflammatory conditions
DE10061137B4 (de) * 2000-12-07 2016-10-06 Takeda Gmbh Neue pharmazeutische Zubereitung
CZ20031895A3 (cs) * 2001-01-31 2004-08-18 Pfizeráproductsáinc Nikotinamidové biarylové deriváty užitečné jako inhibitory isozymů PDE
MXPA03006886A (es) * 2001-01-31 2003-11-13 Pfizer Prod Inc Derivados amida de acido tiazolilico, oxazolilico, pirrolilico e imidazolilico utiles como inhibidores de las isozimas pde4.
CN1537018A (zh) 2001-05-23 2004-10-13 田边制药株式会社 一种用于软骨疾病再生治疗的组合物
JP4364179B2 (ja) 2005-08-15 2009-11-11 株式会社ソニー・コンピュータエンタテインメント 描画処理装置および描画処理方法

Also Published As

Publication number Publication date
JPWO2002094320A1 (ja) 2004-09-02
EP1389467A4 (en) 2007-01-10
US20040180900A1 (en) 2004-09-16
US20100226993A1 (en) 2010-09-09
KR20040007583A (ko) 2004-01-24
ES2427930T3 (es) 2013-11-04
MXPA03010672A (es) 2004-03-02
CN1537018A (zh) 2004-10-13
US20070155652A1 (en) 2007-07-05
JP5112461B2 (ja) 2013-01-09
US8399466B2 (en) 2013-03-19
JP4510383B2 (ja) 2010-07-21
WO2002094320A1 (fr) 2002-11-28
JP2010155850A (ja) 2010-07-15
CA2447618A1 (en) 2002-11-28
EP1389467B1 (en) 2013-07-03
EP1389467A1 (en) 2004-02-18
US8252794B2 (en) 2012-08-28

Similar Documents

Publication Publication Date Title
Su et al. Biofilms: formation, research models, potential targets, and methods for prevention and treatment
AR033918A1 (es) Composicion para acelerar la soldadura de una fractura osea
AR034044A1 (es) Composicion para el tratamiento reconstituyente en enfermedades de cartilago
Ramchandani et al. In vitro and in vivo release of ciprofloxacin from PLGA 50: 50 implants
WO2007130134A3 (en) Controlled release microparticles
Verhorstert et al. In vitro bacterial adhesion and biofilm formation on fully absorbable poly-4-hydroxybutyrate and nonabsorbable polypropylene pelvic floor implants
PE20071139A1 (es) Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido
Shah et al. Effects of local antibiotic delivery from porous space maintainers on infection clearance and induction of an osteogenic membrane in an infected bone defect
NZ595294A (en) Intraocular sustained release drug delivery systems and methods for treating ocular conditions
EP2286799A3 (en) Microspheres for active embolization
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
DE60141567D1 (de) Freisetzungssysteme zur behandlung von restenose und anastomotischer intimaler hyperplasie
UA111162C2 (uk) Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
ATE478656T1 (de) Biologisch abbaubare polymerzusammensetzungen, zusammensetzungen und damit in beziehung stehende verwendungen
ATE540984T1 (de) Blockcopolymere aus polycaprolacton und poly (propylenfumarat)
WO2006039336A3 (en) Conveniently implantable sustained release drug compositions
CR7777A (es) Microesferas antibioticas para el tratamiento de infecciones y osteomielitis
ATE332138T1 (de) Flibanserin zur behandlung extrapyramidaler bewegungsstörungen
JP2005510521A5 (es)
CO5440227A1 (es) Composicion antihelmitica e inyectable mejorada de crecimiento
RU2006126779A (ru) Фармацевтические композиции
ATE476997T1 (de) Zusammensetzung und dosierform mit einer festen oder halbfesten matrix
EA202192878A1 (ru) Способ лечения ребенка с преждевременным половым созреванием центрального генеза с использованием композиции с пролонгированным высвобождением
TW200613012A (en) Sustained-release composition, process for producing the same and use of the same
CN112867484A (zh) 聚合物植入物

Legal Events

Date Code Title Description
FA Abandonment or withdrawal